Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.930.02%
QQQ
707.830.03%
BTC/USD
77493.870.1309%
DIA
527.670.02%
GLD
396.500.06%
TLT
81.830.05%

Larimar Therapeutics Inc

LRMRNASDAQ
Trade with Public
Trade with Public
$3.94
0.123.14%
At close: Sep 1, 5:00 PM EST
$3.96
0.020.51%
After Hours: 4:59 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Larimar Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Larimar Therapeutics (LRMR).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

1S.Buy
10Buy
Consensus RatingBuy# Analysts11Avg. Consensus PT$16Upside to Avg. PT+293.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026WedbushLaura ChicoPT CutOutperform$12→$11
Jul 2, 2026HC Wainwright & Co.Raghuram SelvarajuAssumesBuy$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $7 to $5.
Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.
Benzinga Newsdesk

Nvidia To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper Sandler, Morgan Stanley, Evercore raised price targets.
Avi Kapoor

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $12.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved